Options for combination therapy in type 2 diabetes: Comparison of the ADA/EASD position statement and AACE/ACE algorithm

American Journal of Medicine

Volumn 126, Issue 9 SUPPL.1, 2013, Pages

  Bailey, Timothy ^a  

^a AMCR Institute   (United States)

Author keywords

Algorithm; Patient management; Position statement; Treatment guidelines; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN DERIVATIVE; METFORMIN; SULFONYLUREA DERIVATIVE;

ALGORITHM; ARTICLE; BODY WEIGHT; BONE ATROPHY; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DRUG EFFICACY; FLUID RETENTION; FRACTURE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT REDUCTION;

ALGORITHM; PATIENT MANAGEMENT; POSITION STATEMENT; TREATMENT GUIDELINES; TYPE 2 DIABETES;

ALGORITHMS; CARBAMATES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; METFORMIN; PEPTIDES; PIPERIDINES; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, GLUCAGON; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; VENOMS;

EID: 84882244732     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2013.06.009     Document Type: Article

References (82)

1. J. Unger, and C.G. Parkin Appropriate, timely, and rational treatment of type 2 diabetes mellitus: meeting the challenges of primary care Insulin 4 2009 144 157
2. A.J. Garber, M.J. Abrahamson, and J.I. Barzilay AACE comprehensive diabetes management algorithm 2013 Endocr Pract 19 2013 327 336
3. J.R. Guzmán, R. Lyra, C.A. Aguilar-Salinas ALAD Consensus Group Treatment of type 2 diabetes in Latin America: a consensus statement by the medical associations of 17 Latin American countries. Latin American Diabetes Association Rev Panam Salud Publica 28 2010 463 471
4. S.E. Inzucchi, R.M. Bergenstal, and J.B. Buse Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
5. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada Can J Diabetes 32 Suppl 1 2008 S1 S201
6. A. Sinclair, J.E. Morley, and L. Rodriguez-Mañas Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes J Am Med Dir Assoc 13 2012 497 502
7. A. Saenz, I. Fernandez-Esteban, and A. Mataix Metformin monotherapy for type 2 diabetes mellitus Cochrane Database Syst Rev. 3 2005 CD002966
8. S.E. Kahn, S.M. Haffner, and M.A. Heise Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2006 2427 2443 (Pubitemid 44903747)
9. L.F. Meneghini Intensifying insulin therapy: what options are available to patients with type 2 diabetes? Am J Med 126 Suppl 2013 S28 S37
10. A. Philis-Tsimikas Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control Am J Med 126 Suppl 2013 S21 S27
11. D.M. Nathan, J.B. Buse, and M.B. Davidson Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
12. H.W. Rodbard, and P.S. Jellinger A critique of the 2012 ADA/EASD position statement Diabetologia 55 2012 2850 2852
13. US Food and Drug Administration (FDA). (Glucophage) Metformin product insert. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/ 020357s031, 021202s016lbl.pdf. Accessed May 13, 2013.
14. S.E. Inzucchi Oral antihyperglycemic therapy for type 2 diabetes JAMA 287 2002 360 372 (Pubitemid 34256388)
15. J. Bryan, A. Crane, W.H. Vila-Carriles, A.P. Babenko, and L. Aguilar-Bryan Insulin secretagogues, sulfonylurea receptors and K(ATP) channels Curr Pharm Des 11 2005 2699 2716 (Pubitemid 41051879)
16. W.L. Bennett, N.M. Maruthur, and S. Singh Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations Ann Intern Med 154 2011 602 613 Erratum in: Ann Intern Med. 2011;155:67-68
17. R. Hillson Diabetes Care: A Practical Manual 2008 Oxford University Press New York
18. D.J. Drucker, S.I. Sherman, and F.S. Gorelick Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits Diabetes Care 33 2010 428 433
19. M.B. Graal, and B.H. Wolffenbuttel The use of sulphonylureas in the elderly Drugs Aging 15 1999 471 481 (Pubitemid 30025750)
20. O.J. Phung, J.M. Scholle, and M. Talwar Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes JAMA 303 2010 1410 1418
21. D.M. Nathan, J.B. Buse, and M.B. Davidson Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 29 2006 1963 1972 (Pubitemid 44156663)
22. P. Raskin, L. Klaff, and J. McGill Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin Diabetes Care 26 2003 2063 2068 (Pubitemid 41184253)
23. W.J. Malaisse Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus Treat Endocrinol 2 2003 401 414 (Pubitemid 37462239)
24. J. Rosenstock, D.R. Hassman, and R.D. Madder Repaglinide versus nateglinide monotherapy: a randomized, multicenter study Diabetes Care 27 2004 1265 1270 (Pubitemid 38679968)
25. US Food and Drug Administration (FDA). (Prandin) Repaglinide product insert. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 020741s040lbl.pdf. Accessed May 13, 2013.
26. C.R. Dormuth, G. Carney, B. Carleton, K. Bassett, and J.M. Wright Thiazolidinediones and fractures in men and women Arch Intern Med 169 2009 1395 1402
27. R.E. Aubert, V. Herrera, W. Chen, S.M. Haffner, and M. Pendergrass Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes Diabetes Obes Metab 12 2010 716 721
28. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471 (Pubitemid 46919772)
29. S.E. Nissen, and K. Wolski Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality Arch Intern Med 170 2010 1191 1201
30. B.M. Cheung Behind the rosiglitazone controversy Expert Rev Clin Pharmacol 3 2010 723 725
31. R. Wilcox, S. Kupfer, E. Erdmann, and PROactive Study investigators Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10) Am Heart J 155 2008 712 717
32. E. Erdmann, B. Charbonnel, and R. Wilcox Thiazolidinediones and cardiovascular risk - a question of balance Curr Cardiol Rev 5 2009 155 165
33. V. Fonseca, A. Jawa, and S. Asnani Commentary: the PROactive Study - the glass is half full J Clin Endocrinol Metab 91 2006 25 27 (Pubitemid 43069110)
34. J.S. Skyler PROactive: a sad tale of inappropriate analysis and unjustified interpretation Clin Diabetes 24 2 2006 63 65
35. J. Dormandy, M. Bhattacharya, A.R. van Troostenburg de Bruyn PROactive investigators Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive Drug Saf 32 2009 187 202
36. A.M. Lincoff, K. Wolski, S.J. Nicholls, and S.E. Nissen Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 298 10 2007 1180 1188 (Pubitemid 47403104)
37. J.A. Dormandy, B. Charbonnel, D.J. Eckland PROactive investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 9493 2005 1279 1289 (Pubitemid 41416583)
38. D. Hillaire-Buys, and J.L. Faillie Pioglitazone and bladder cancer Lancet 378 9802 2011 1543 1544 author reply 1544-1545
39. Z. Zhu, Z. Shen, and Y. Lu Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis Diabetes Res Clin Pract 98 2012 159 163
40. A. Neumann, A. Weill, and P. Ricordeau Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study Diabetologia 55 2012 1953 1962
41. L. Azoulay, H. Yin, and K.B. Filion The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study BMJ 344 2012 e3645 10.1136/bmj.e3645
42. European Medicines Agency. European Medicines Agency recommends new contraindications and warnings for pioglitazone to reduce small increased risk of bladder cancer. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Press-release/2011/07/WC500109176.pdf. Accessed May 13, 2013.
43. US Food and Drug Administration (FDA). FDA drug safety communication: update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. 2011. Available at: http://www.fda.gov/drugs/drugsafety/ ucm259150.htm. Accessed May 13, 2013.
44. C.H. Tseng Pioglitazone and bladder cancer: a population-based study of Taiwanese Diabetes Care 35 2012 278 280
45. C.H. Tseng Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? J Formos Med Assoc 111 2012 123 131
46. A. Ferrara, J.D. Lewis, and C.P. Quesenberry Jr. Cohort study of pioglitazone and cancer incidence in patients with diabetes Diabetes Care 34 2011 923 929
47. J.D. Lewis, A. Ferrara, and T. Peng Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study Diabetes Care 34 2011 916 922
48. D. Hillaire-Buys, and J.L. Faillie Pioglitazone and the risk of bladder cancer BMJ 344 2012 e3500
49. R.E. Ryder Pioglitazone and bladder cancer Lancet 378 9802 2011 1544 author reply 1544-1545
50. M.A. Nauck Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications Am J Med 124 1 Suppl 2011 S3 S18
51. L.K. Phillips, and J.B. Prins Update on incretin hormones Ann N Y Acad Sci 1243 2011 E55 E74
52. J.F. Gautier, S.P. Choukem, and J. Girard Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes Diabetes Metab 34 2008 S65 S72
53. K.J. Hare, T. Vilsbøll, and M. Asmar The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action Diabetes 59 2010 1765 1770
54. P.E. Cryer Hypoglycemia: still the limiting factor in the glycemic management of diabetes Endocr Pract 14 2008 760 766
55. P.E. Cryer Elimination of hypoglycemia from the lives of people affected by diabetes Diabetes 60 2011 24 27
56. R.M. Bergenstal, C. Wysham, L. Macconell DURATION-2 Study Group Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 376 2010 431 439
57. C. Wysham, R. Bergenstal, and J. Malloy DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide Diabet Med 28 2011 705 714
58. H.W. Rodbard, P.S. Jellinger, and J.A. Davidson Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract 15 2009 540 559
59. R.E. Pratley, M. Nauck, and T. Bailey Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Lancet 375 2010 1447 1456
60. R. Pratley, M. Nauck, T. Bailey 1860-LIRA-DPP-4 Study Group One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial Int J Clin Pract 65 2011 397 407
61. R.E. Pratley, M.A. Nauck, T. Bailey for the 1860-LIRA-DPP-4 Study Group Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial Diabetes Care 35 2012 1986 1993
62. J.B. Buse, J. Rosenstock, and G. Sesti Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 2009 39 47
63. J.B. Buse, G. Sesti, and W.E. Schmidt Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents Diabetes Care 33 2010 1300 1303
64. J.B. Buse, M.A. Nauck, and T. Forst Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study Diabetologia 54 Suppl 1 2011 S38
65. R. Pratley, A. Barnett, and M. Feinglos Efficacy and safety of once-weekly (QW) albiglutide vs. once-daily (QD) liraglutide in type 2 diabetes (T2D) inadequately controlled on oral agents: Harmony 7 trial Diabetes Care 60 Suppl 1 2012 A240 (Abstract 945-P)
66. C.M. Perry Liraglutide: a review of its use in the management of type 2 diabetes mellitus Drugs 71 2011 2347 2373
67. R.K. Campbell Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus Clin Ther 33 2011 511 527
68. S.L. Anderson, and J.M. Trujillo Association of pancreatitis with glucagon-like peptide-1 agonist use Ann Pharmacother 44 2010 904 909
69. US Food and Drug Administration (FDA). (Victoza) Liraglutide product insert. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 022341lbl.pdf. Accessed May 13, 2013.
70. D.J. Drucker, S.I. Sherman, R.M. Bergenstal, and J.B. Buse The safety of incretin-based therapies-review of the scientific evidence J Clin Endocrinol Metab 96 2011 2027 2031
71. US Food and Drug Administration (FDA). (Bydureon) Exenatide product insert. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 022200s000lbl.pdf. Accessed May 13, 2013.
72. L. Bjerre Knudsen, L.W. Madsen, and S. Andersen Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation Endocrinology 151 2010 1473 1486
73. B. Waser, K. Beetschen, and N.S. Pellegata Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy Neuroendocrinology 94 2011 291 301
74. L. Hegedüs, A.C. Moses, and M. Zdravkovic GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide J Clin Endocrinol Metab 96 2011 853 860
75. K. Goossen, and S. Gräber Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis Diabetes Obes Metab 2012 Apr 20 10.1111/j.1463-1326. 2012.01610.x [Epub ahead of print]
76. M. Monami, I. Dicembrini, and D. Martelli Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials Curr Med Res Opin 27 Suppl 3 2011 57 64
77. T. Karagiannis, P. Paschos, and K. Paletas Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis BMJ 344 2012 e1369 10.1136/bmj.e1369
78. C.F. Deacon, E. Mannucci, and B. Ahrén Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis Diabetes Obes Metab 14 2012 762 767
79. L.K. Golightly, C.C. Drayna, and M.T. McDermott Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors Clin Pharmacokinet 51 2012 501 504
80. US Food and Drug Administration (FDA). (Januvia) Sitagliptin product insert. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 021995s023lbl.pdf. Accessed May 13, 2013.
81. US Food and Drug Administration (FDA). (Onglyza) Saxagliptin product insert. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 022350s004lbl.pdf. Accessed May 13, 2013.
82. W. Kothny, Q. Shao, and P.H. Groop One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal insufficiency Diabetes Obes Metab 14 2012 1032 1039